{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:23:11Z","timestamp":1792444991730,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.pbb.2023.173607","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T03:18:06Z","timestamp":1691119086000},"page":"173607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["A systematic review of cannabidiol trials in neurodevelopmental disorders"],"prefix":"10.1016","volume":"230","author":[{"given":"Nina-Francecsa","family":"Parrella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron Thomas","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Gregory","family":"Enticott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Barhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Simone","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talitha Caitlyn","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2023.173607_bb0005","article-title":"A double-blind, randomised, controlled crossover trial of cannabis in adults with tourette syndrome","author":"Abi-Jaoude","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"issue":"6","key":"10.1016\/j.pbb.2023.173607_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"Almeida","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.pbb.2023.173607_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.P3.318","article-title":"Cannabidiol based medical cannabis in children with autism-a retrospective feasibility study (P3.318)","volume":"90","author":"Aran","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pbb.2023.173607_bb0025","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems\u2014a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol. Autism"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomised trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0040","first-page":"44","article-title":"The relationship between endocannabinoid system and cognitive problems in autism","volume":"7","author":"Bagherzadeh","year":"2012","journal-title":"Iran. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.pbb.2023.173607_bb0050","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.3390\/ijms23105734","article-title":"Exploration of multiverse activities of endocannabinoids in biological systems","volume":"23","author":"Behl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. Drug Saf."},{"issue":"6","key":"10.1016\/j.pbb.2023.173607_bb0060","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s42238-021-00108-7","article-title":"CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature","volume":"3","author":"Bilge","year":"2021","journal-title":"J. Cannabis Res."},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0070","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pbb.2023.173607_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2015.00365","article-title":"Brain MR spectroscopy in autism spectrum disorder\u2014the GABA excitatory\/inhibitory imbalance theory revisited","volume":"9","author":"Brix","year":"2015","journal-title":"Front. Hum. Neurosci."},{"issue":"3","key":"10.1016\/j.pbb.2023.173607_bb0080","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10803-015-2619-y","article-title":"Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies","volume":"46","author":"Brondino","year":"2016","journal-title":"J. Autism Dev. Disord."},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/mpr.1466","article-title":"Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioral problems: outcome measures for adult autism trials","volume":"24","author":"Brugha","year":"2015","journal-title":"Int. J. Methods Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.pbb.2023.173607_bb0090","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bmc.2015.01.059","article-title":"Cannabidiol (CBD) and its analogs: a review of their effects on inflammation","volume":"23","author":"Burstein","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pbb.2023.173607_bb0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fpsyt.2017.00069","article-title":"Autism spectrum disorders and schizophrenia spectrum disorders: excitation\/inhibition imbalance and developmental trajectories","volume":"8","author":"Canitano","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"753","key":"10.1016\/j.pbb.2023.173607_bb0100","first-page":"274","article-title":"Excitation\/inhibition modulators in autism spectrum disorder: current clinical research","volume":"15","author":"Canitano","year":"2021","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","article-title":"Endocannabinoid signaling and synaptic function","volume":"76","author":"Castillo","year":"2012","journal-title":"Neuron"},{"issue":"17","key":"10.1016\/j.pbb.2023.173607_bb0110","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e3181a2e8f6","article-title":"Altered anandamide degradation in attention-deficit\/hyperactivity disorder","volume":"72","author":"Centonze","year":"2009","journal-title":"Neurology"},{"issue":"540","key":"10.1016\/j.pbb.2023.173607_bb0115","first-page":"837","article-title":"Methylphenidate for attention-deficit and hyperactivity disorder in adult patients with substance use disorders: good clinical practice","volume":"11","author":"Chamakalayil","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0120","first-page":"24","article-title":"Long-term safety and efficacy of Cannabidiol (CBD) treatment in Lennox Gastaut syndrome: Results overall and for patients completing 1\u20133\u00a0years of an open-label extension (GWPCARE5)","volume":"27","author":"Chin","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0125","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/cap.2014.0112","article-title":"Relationship among Glutamine, \u03b3-aminobutyric acid, and social cognition in autism spectrum disorders","volume":"25","author":"Cochran","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.pbb.2023.173607_bb0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropsychologia.2018.11.008","article-title":"Reduced connectivity between mentalizing and mirror systems in autism spectrum condition","volume":"122","author":"Cole","year":"2019","journal-title":"Neuropsychologia"},{"issue":"8","key":"10.1016\/j.pbb.2023.173607_bb0140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2023.173607_bb0145","series-title":"Targeting the Endocannabinoid System in the Treatment of ADHD","first-page":"7","author":"Dawson","year":"2021"},{"issue":"3","key":"10.1016\/j.pbb.2023.173607_bb0150","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.pbb.2023.173607_bb0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study","volume":"6","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2023.173607_bb0160","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.biopsych.2013.02.011","article-title":"Shared and distinct intrinsic functional network centrality in autism and attention-deficit\/hyperactivity disorder","volume":"74","author":"Di Martino","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0165","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fneur.2020.00829","article-title":"Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study","volume":"11","author":"D'Onofrio","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.pbb.2023.173607_bb0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.31887\/DCNS.2012.14.3\/cdoyle","article-title":"Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan","volume":"14","author":"Doyle","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.pbb.2023.173607_bb0175","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":"Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis","volume":"33","author":"D'Souza","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1756285610390261","article-title":"Treatment strategies for tics in Tourette syndrome","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0185","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bcp.14399","article-title":"A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability","volume":"87","author":"Efron","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0190","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/dmcn.14548","article-title":"Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: A randomized controlled trial","volume":"62","author":"Fairhurst","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1570159X17666190903103923","article-title":"The \u201c entourage effect\u201d: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders","volume":"18","author":"Ferber","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2023.173607_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2014.00117","article-title":"Factor analysis demonstrates a common schizoidal phenotype within autistic and schizotypal tendency: implications for neuroscientific studies","volume":"5","author":"Ford","year":"2014","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.nicl.2017.07.009","article-title":"Increased glutamate\/GABA+ ratio in a shared autistic and schizotypal trait phenotype termed social disorganisation","volume":"16","author":"Ford","year":"2017","journal-title":"NeuroImage Clin."},{"key":"10.1016\/j.pbb.2023.173607_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroimage.2013.05.068","article-title":"GABA estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation","volume":"86","author":"Gaetz","year":"2014","journal-title":"NeuroImage"},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/1566524015666150303003028","article-title":"Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders","volume":"15","author":"Gao","year":"2015","journal-title":"Curr. Mol. Med."},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0220","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00018-020-03649-x","article-title":"Molecular and neurocircuitry mechanisms of social avoidance","volume":"78","author":"Gellner","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.pbb.2023.173607_bb0225","article-title":"The Yin and Yang of cannabis: a systematic review of human neuroimaging evidence of the differential effects of \u03949-tetrahydrocannabinol and cannabidiol","author":"Gunasekera","year":"2020","journal-title":"Biol. Psychiatry: Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.pbb.2023.173607_bb0230","series-title":"Proceedings of the Third International Conference on Medical and Health Informatics 2019 - ICMHI 2019","first-page":"21","article-title":"Aberrant functional connectivity dynamics of superior temporal sulcus and its associations with GABA genes expression in autism","author":"Guo","year":"2019"},{"issue":"7416","key":"10.1016\/j.pbb.2023.173607_bb0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature11356","article-title":"Autistic-like behavior in Scn1a+\/\u2212 mice and rescue by enhanced GABA-mediated neurotransmission","volume":"489","author":"Han","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pbb.2023.173607_bb0240","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.neuron.2014.01.016","article-title":"Enhancement of inhibitory neurotransmission by GABA A receptors having \u03b1 2,3 -subunits ameliorates behavioral deficits in a mouse model of autism","volume":"81","author":"Han","year":"2014","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0245","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10803-010-1065-0","article-title":"Non-invasive evaluation of the GABAergic\/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 Tesla instrument","volume":"41","author":"Harada","year":"2011","journal-title":"J. Autism Dev. Disord."},{"issue":"13","key":"10.1016\/j.pbb.2023.173607_bb0250","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"issue":"11","key":"10.1016\/j.pbb.2023.173607_bb0255","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3109\/10826084.2015.1018545","article-title":"ADHD and marijuana-use expectancies in young adulthood","volume":"50","author":"Harty","year":"2015","journal-title":"Subst. Use Misuse"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-019-9277-x","article-title":"A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome","volume":"11","author":"Heussler","year":"2019","journal-title":"J. Neurodev. Disord."},{"issue":"8\u20139","key":"10.1016\/j.pbb.2023.173607_bb0265","first-page":"672","article-title":"An open-label, tolerability and efficacy study of ZYN002 (cannabidiol) administered as a transdermal gel to children and adolescents with 22Q11.2 deletion syndrome (INSPIRE)","volume":"66","author":"Heussler","year":"2022","journal-title":"J. Intellect. Disabil. Res."},{"key":"10.1016\/j.pbb.2023.173607_bb0270","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2018.07.009","article-title":"The endocannabinoid system in mental disorders: evidence from human brain studies","volume":"157","author":"Ibarra-Lecue","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pbb.2023.173607_bb0280","series-title":"Qb Test Technical Manual","author":"Iberstadt","year":"2012"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0285","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.pbb.2023.173607_bb0290","series-title":"Potential Cannabis Antagonists for Marijuana Intoxication","first-page":"9","author":"Ishak","year":"2018"},{"key":"10.1016\/j.pbb.2023.173607_bb0295","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2023.1256","article-title":"Cannabis use disorder and subsequent risk of psychotic and nonpsychotic unipolar depression and bipolar disorder","author":"Jefsen","year":"2023","journal-title":"JAMA Psychiatry."},{"issue":"42","key":"10.1016\/j.pbb.2023.173607_bb0300","doi-asserted-by":"crossref","first-page":"11,229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.169","article-title":"Endocannabinoid signaling in social functioning: An RDoC perspective","volume":"6","author":"Karhson","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism"},{"key":"10.1016\/j.pbb.2023.173607_bb0320","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","article-title":"Alterations in the endocannabinoid system in the rat valproic acid model of autism","volume":"249","author":"Kerr","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0325","first-page":"389","article-title":"Treatment of adults with attention-deficit\/hyperactivity disorder","volume":"4","author":"Kolar","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pbb.2023.173607_bb0330","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.neubiorev.2019.09.023","article-title":"Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence","volume":"107","author":"Krinzinger","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2023.173607_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.643442","article-title":"Cannabidiol and neurodevelopmental disorders in children","volume":"12","author":"Kwan Cheung","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"20","key":"10.1016\/j.pbb.2023.173607_bb0340","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor: Negative allosteric modulation of CB 1 by cannabidiol","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2023.173607_bb0345","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14740\/jocmr4090","article-title":"Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials","volume":"12","author":"Larsen","year":"2020","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.pbb.2023.173607_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107962","article-title":"Chronic cannabidiol (CBD) administration induces anticonvulsant and antiepileptogenic effects in a genetic model of epilepsy","volume":"119","author":"Lazarini-Lopes","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.pbb.2023.173607_bb0355","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: A review","volume":"40","author":"LeClerc","year":"2015","journal-title":"P & T"},{"issue":"3","key":"10.1016\/j.pbb.2023.173607_bb0360","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0365","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0883073818773028","article-title":"Medical cannabis for pediatric moderate to severe complex motor disorders","volume":"33","author":"Libzon","year":"2018","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0370","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Braz. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.pbb.2023.173607_bb0375","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0380","series-title":"Cannabinoids","first-page":"299","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"168","author":"Mackie","year":"2005"},{"issue":"5","key":"10.1016\/j.pbb.2023.173607_bb0385","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pbb.2023.173607_bb0390","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.nicl.2014.10.005","article-title":"GABA and glutamate in schizophrenia: a 7\u00a0T 1H-MRS study","volume":"6","author":"Marsman","year":"2014","journal-title":"NeuroImage Clin."},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0395","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12264-017-0100-y","article-title":"An overview of autism spectrum disorder, heterogeneity and treatment options","volume":"33","author":"Masi","year":"2017","journal-title":"Neurosci. Bull."},{"issue":"5","key":"10.1016\/j.pbb.2023.173607_bb0400","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.pbb.2023.173607_bb0405","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1111\/bph.14435","article-title":"Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling","volume":"175","author":"Melancia","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2023.173607_bb0410","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.pbb.2023.173607_bb0415","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41386-020-0671-6","article-title":"Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome","volume":"45","author":"M\u00fcller-Vahl","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pbb.2023.173607_bb0420","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1038\/tp.2013.26","article-title":"Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies","volume":"3(","author":"Nurmi","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0425","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.brainres.2010.09.021","article-title":"Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism","volume":"1380","author":"Oblak","year":"2011","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0430","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5409\/wjcp.v11.i2.120","article-title":"Classification, prevalence and integrated care for neurodevelopmental and child mental health disorders: a brief overview for paediatricians","volume":"11","author":"Ogundele","year":"2022","journal-title":"World J. Clin. Pediatr."},{"key":"10.1016\/j.pbb.2023.173607_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.conb.2014.03.017","article-title":"Endocannabinoid-mediated retrograde modulation of synaptic transmission","volume":"29","author":"Ohno-Shosaku","year":"2014","journal-title":"Curr. Opin. Neurobiol."},{"issue":"1\u20133","key":"10.1016\/j.pbb.2023.173607_bb0440","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.schres.2007.10.024","article-title":"Neural bases for impaired social cognition in schizophrenia and autism spectrum disorders","volume":"99","author":"Pinkham","year":"2008","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0445","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41398-019-0654-8","article-title":"Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy","volume":"9","author":"Pretzsch","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0450","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/0269881119858306","article-title":"The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD)","volume":"33","author":"Pretzsch","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.pbb.2023.173607_bb0455","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","article-title":"Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder","volume":"44","author":"Pretzsch","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0465","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13229-021-00454-6","article-title":"Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomised trial of cannabidivarin","volume":"12","author":"Pretzsch","year":"2021","journal-title":"Mol. Autism"},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0470","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/aur.1691","article-title":"Reduced GABA and altered somatosensory function in children with autism spectrum disorder: Abnormal GABA and touch in ASD","volume":"10","author":"Puts","year":"2017","journal-title":"Autism Res."},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0475","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ebch.786","article-title":"Commentary on \u2018Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)\u2019","volume":"6","author":"Reiersen","year":"2011","journal-title":"Evid Based Child Health"},{"key":"10.1016\/j.pbb.2023.173607_bb0480","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuroimage.2013.01.045","article-title":"Decreased left perisylvian GABA concentration in children with autism and unaffected siblings","volume":"86","author":"Rojas","year":"2014","journal-title":"NeuroImage"},{"issue":"2","key":"10.1016\/j.pbb.2023.173607_bb0485","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/WCO.0b013e328336eb13","article-title":"Three hypotheses for developmental defects that may underlie some forms of autism spectrum disorder","volume":"23","author":"Rubenstein","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.pbb.2023.173607_bb0490","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-319-20825-1_9","article-title":"Endocannabinoids and mental disorders","volume":"231","author":"Rubino","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.pbb.2023.173607_bb0495","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"issue":"6","key":"10.1016\/j.pbb.2023.173607_bb0500","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1017\/S1355617721000114","article-title":"An observational, longitudinal study of cognition in medical cannabis patients over the course of 12\u00a0months of treatment: preliminary results","volume":"27","author":"Sagar","year":"2021","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.pbb.2023.173607_bb0505","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fphar.2019.00226","article-title":"Single and synergistic effects of cannabidiol and \u0394-9-tetrahydrocannabinol on zebrafish models of neuro-hyperactivity","volume":"10","author":"Samarut","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0510","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3934\/molsci.2019.1.27","article-title":"Endocannabinoid system involvement in autism spectrum disorder: An overview with potential therapeutic applications","volume":"6","author":"Schultz","year":"2019","journal-title":"AIMS Mol. Sci."},{"issue":"401","key":"10.1016\/j.pbb.2023.173607_bb0515","doi-asserted-by":"crossref","first-page":"eaah6733","DOI":"10.1126\/scitranslmed.aah6733","article-title":"Modulation of prefrontal cortex excitation\/inhibition balance rescues social behavior in CNTNAP2 -deficient mice","volume":"9","author":"Selimbeyoglu","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0520","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.182","article-title":"Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid","volume":"6","author":"Servadio","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0525","doi-asserted-by":"crossref","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in anxiety and sleep: A large case series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm. J."},{"issue":"4","key":"10.1016\/j.pbb.2023.173607_bb0530","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pedhc.2011.02.008","article-title":"Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis","volume":"26","author":"Sharma","year":"2012","journal-title":"J. Pediatr. Health Care"},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0535","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/npp.2015.66","article-title":"GABAB receptor agonist R-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism","volume":"40","author":"Silverman","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0540","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5603\/PJNNS.a2022.0015","article-title":"Cannabis and cannabinoids: pharmacology and therapeutic potential","volume":"56","author":"\u015amiarowska","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0545","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41380-019-0426-0","article-title":"Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders","volume":"24","author":"Sohal","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0550","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0555","first-page":"1","article-title":"Cannabis improves symptoms of ADHD","volume":"3","author":"Strohbeck-Kuehner","year":"2008","journal-title":"Cannabinoids"},{"issue":"6","key":"10.1016\/j.pbb.2023.173607_bb0560","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/10870547211050949","article-title":"Self-reported effects of cannabis on ADHD Symptoms, ADHD medication side effects, and ADHD-related executive dysfunction","volume":"26","author":"Stueber","year":"2022","journal-title":"J. Atten. Disord."},{"issue":"5","key":"10.1016\/j.pbb.2023.173607_bb0565","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-2005-873156","article-title":"The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. a proton magnetic resonance spectroscopy (1H MRS) study","volume":"38","author":"Szulc","year":"2005","journal-title":"Pharmacopsychiatry"},{"issue":"12","key":"10.1016\/j.pbb.2023.173607_bb0570","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/mp.2014.62","article-title":"Disturbed cingulate glutamate metabolism in adults with high-functioning autism spectrum disorder: evidence in support of the excitatory\/inhibitory imbalance hypothesis","volume":"19","author":"Tebartz van Elst","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173607_bb0575","first-page":"S27","article-title":"Social play in adolescence: how its observation may help us understand developmental disorders","volume":"25","author":"Trezza","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2023.173607_bb0580","doi-asserted-by":"crossref","first-page":"10,796","DOI":"10.18632\/aging.202951","article-title":"Potential role of cannabidiol in Parkinson\u2019s disease by targeting the WNT\/\u03b2-catenin pathway, oxidative stress and inflammation","volume":"13","author":"Vall\u00e9e","year":"2021","journal-title":"Aging"},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0585","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.mayocp.2019.01.003","article-title":"Clinicians\u2019 guide to cannabidiol and hemp oils","volume":"94","author":"VanDolah","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"23","key":"10.1016\/j.pbb.2023.173607_bb0590","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0595","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/can.2015.0008","article-title":"Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment","volume":"1","author":"Wei","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0600","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12916-020-01585-y","article-title":"Guidance for identification and treatment of individuals with attention deficit\/hyperactivity disorder and autism spectrum disorder based upon expert consensus","volume":"18","author":"Young","year":"2020","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.pbb.2023.173607_bb0605","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/ijms18091916","article-title":"The endocannabinoid system and autism spectrum disorders: insights from animal models","volume":"18","author":"Zamberletti","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.pbb.2023.173607_bb0610","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.pbb.2023.173607_bb0615","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jneumeth.2008.04.012","article-title":"An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF","volume":"172","author":"Zou","year":"2008","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.pbb.2023.173607_bb0620","series-title":"Biology, Pharmacology, Diagnosis, and Treatment","first-page":"e131","article-title":"The anxiolytic effects of cannabidiol (CBD)","author":"Zuardi","year":"2017"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:45:10Z","timestamp":1758775510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305723000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":120,"alternative-id":["S0091305723000941"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173607","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of cannabidiol trials in neurodevelopmental disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"173607"}}